[go: up one dir, main page]

MX2016004063A - Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta. - Google Patents

Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.

Info

Publication number
MX2016004063A
MX2016004063A MX2016004063A MX2016004063A MX2016004063A MX 2016004063 A MX2016004063 A MX 2016004063A MX 2016004063 A MX2016004063 A MX 2016004063A MX 2016004063 A MX2016004063 A MX 2016004063A MX 2016004063 A MX2016004063 A MX 2016004063A
Authority
MX
Mexico
Prior art keywords
subtype
pcv2b
pcv2
protein
pcv2 orf2
Prior art date
Application number
MX2016004063A
Other languages
English (en)
Other versions
MX373884B (es
Inventor
Eric Martin Vaughn
Christine Margaret Muehlenthaler
Luis Alejandro Hernández
Gregory Haiwick
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of MX2016004063A publication Critical patent/MX2016004063A/es
Publication of MX373884B publication Critical patent/MX373884B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se divulgan métodos de vacunación para controlar la infección por PCV2 con diferentes subtipos de PCV2. Específicamente, una proteína PCV2 ORF2 subtipo b (PCV2b) o las composiciones inmunogénicas que comprenden una proteína PCV2b ORE2 se usan en un método para el tratamiento o la prevención de una infección por PCV2 del mismo subtipo PCV2b y/o un subtipo diferente; la reducción, la prevención o el tratamiento de los signos clínicos causados por la infección por PCV2 del mismo subtipo PCV2b o un subtipo diferente; y/o la prevención o el tratamiento de una enfermedad causada por una infección por PCV2 del mismo subtipo PCV2b y/o un subtipo diferente. La presente invención se refiere en particular a las proteínas PCV2 ORF2 subtipo b (PCV2b) caracterizadas porque contienen por lo menos una mutación del bucle BC de modo tal que la proteína expresada se expresa preferentemente en una cantidad más alta comparado con una proteína PCV2 ORF2 que no contiene la mutación.
MX2016004063A 2013-10-02 2014-10-02 Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta. MX373884B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361885871P 2013-10-02 2013-10-02
PCT/US2014/058793 WO2015051099A1 (en) 2013-10-02 2014-10-02 Pcv2 orf2 protein variant and virus like particles composed thereof

Publications (2)

Publication Number Publication Date
MX2016004063A true MX2016004063A (es) 2016-06-06
MX373884B MX373884B (es) 2020-03-26

Family

ID=51795768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004063A MX373884B (es) 2013-10-02 2014-10-02 Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta.

Country Status (12)

Country Link
US (6) US9505808B2 (es)
EP (1) EP3052516B1 (es)
JP (1) JP6778104B2 (es)
KR (2) KR102409183B1 (es)
CN (1) CN105658660A (es)
AU (1) AU2014329524B2 (es)
CA (1) CA2924228C (es)
DK (1) DK3052516T3 (es)
EA (1) EA035265B1 (es)
ES (1) ES2778425T3 (es)
MX (1) MX373884B (es)
WO (1) WO2015051099A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
PT3127551T (pt) 2005-12-29 2020-10-09 Boehringer Ingelheim Animal Health Usa Inc Composição imunogénica de pcv2 para atenuar os sintomas clínicos em porcos
PL1968630T3 (pl) 2005-12-29 2018-08-31 Boehringer Ingelheim Vetmedica, Inc. Multiwalentne immunogenne kompozycje PCV2
EP2859900A1 (en) 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
EP2242511A4 (en) 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
KR102409183B1 (ko) 2013-10-02 2022-06-15 베링거 인겔하임 애니멀 헬스 유에스에이 인크. Ｐｃｖ2 ｏｒｆ2 단백질 변이체 및 이로 이루어진 바이러스 유사 입자
US10555994B2 (en) 2015-03-30 2020-02-11 Boehringer Ingelheim Animal Health USA Inc. PCV2 ORF2 carrier platform
MX394778B (es) 2015-05-14 2025-03-21 Boehringer Ingelheim Animal Health Usa Inc Método para la producción de circovirus porcino y vacunas pcv2.
CN104984335A (zh) * 2015-07-14 2015-10-21 浙江诺倍威生物技术有限公司 猪圆环病毒双亚型orf2共表达载体构建及疫苗制备
CN109195623A (zh) * 2016-03-07 2019-01-11 弗吉尼亚科技知识产权有限公司 嵌合型猪圆环病毒2型(pcv2)疫苗
US10431889B2 (en) * 2016-04-22 2019-10-01 The Charles Stark Draper Laboratory, Inc. Low-loss compact transmit impedance matching tuning technique
CN106399350B (zh) * 2016-09-07 2020-02-21 复旦大学 一种猪圆环病毒ii型病毒样颗粒疫苗及其制备方法
CN106399138B (zh) * 2016-09-07 2019-11-12 复旦大学 猪圆环病毒ii型口服病毒样颗粒疫苗及其制备方法和应用
RS67051B1 (sr) * 2016-11-03 2025-08-29 Boehringer Ingelheim Vetmedica Gmbh Vakcina protiv svinjskog parvovirusa
CN106834241B (zh) * 2017-03-02 2021-01-19 扬州大学 嵌合型猪圆环病毒活疫苗c1-402株及其构建方法
CN106834242B (zh) * 2017-03-02 2021-02-23 扬州大学 嵌合型猪圆环病毒活疫苗c1-233株及其构建方法
CN107245477B (zh) * 2017-06-06 2020-06-30 广东海大畜牧兽医研究院有限公司 一种猪圆环病毒2型病毒样颗粒的制备方法及通过该方法获得的病毒样颗粒
CA3078281C (en) * 2017-10-17 2023-02-21 Intervet International B.V. Recombinant expression of pcv2b orf2 protein in insect cells
CN108484725A (zh) * 2018-03-16 2018-09-04 广东海大畜牧兽医研究院有限公司 一种区分检测pcv2野毒抗体与疫苗抗体的多肽及其在elisa检测试剂盒中的应用
CN110358742B (zh) * 2019-07-05 2020-12-22 武汉科前生物股份有限公司 猪圆环病毒2b型和2d型的二价亚单位疫苗及其制备方法
CN111415356B (zh) * 2020-03-17 2020-12-29 推想医疗科技股份有限公司 肺炎征象的分割方法、装置、介质及电子设备
CN112010949B (zh) * 2020-08-03 2021-07-27 山东绿都生物科技有限公司 一种重组pcv2病毒样颗粒蜂胶疫苗及其制备方法
CN114250259B (zh) * 2020-09-21 2024-07-19 成都史纪生物制药有限公司 一种猪圆环2型病毒Cap蛋白病毒样颗粒的发酵培养基
TWI867524B (zh) * 2022-05-09 2024-12-21 福又達生物科技股份有限公司 豬環狀病毒第二型及豬瘟病毒次單位雙價疫苗
TW202508619A (zh) 2023-05-03 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 用於誘導免疫反應之方法
KR20260005383A (ko) 2023-05-03 2026-01-09 베링거잉겔하임베트메디카게엠베하 돼지에 의한 자가 투여에 유용한 면역원성 조성물
CN118063562B (zh) * 2024-03-11 2025-04-01 天康生物制药有限公司 优化的猪圆环病毒2型Cap蛋白及其病毒样颗粒和应用

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
DE3875762T2 (de) 1987-03-17 1993-05-13 Akzo Nv Adjuvanzienmischung.
US5069901A (en) 1988-02-03 1991-12-03 Jones Elaine V Preparation of a recombinant subunit vaccine against pseudorabies infection
HK1000113A1 (en) 1989-01-23 1997-12-05 Auspharm International Ltd. Vaccine composition
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5202430A (en) 1990-01-16 1993-04-13 University Of Tennessee Transmissible gastroenteritis virus genes
AU657907B2 (en) 1990-05-29 1995-03-30 Wyeth Holdings Corporation Mycoplasma hyopneumoniae vaccine
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
GB9023111D0 (en) 1990-10-24 1990-12-05 Wellcome Found Expression system
EP0555366B1 (en) 1990-11-01 2000-06-28 Iowa State University Research Foundation, Inc. Bacterial attenuation method and vaccine
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
MX9204885A (es) 1991-08-26 1994-05-31 Boehringer Animal Health Inc Composicion de vacuna que comprende virus del sindrome de infertilidad y respiratorio de los cerdos.
US5580557A (en) 1991-10-09 1996-12-03 Iowa State University Research Foundation, Inc. Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
NZ285324A (en) 1994-05-10 1998-08-26 American Home Prod Vaccine containing modified live bovine respiratory syncytial virus (brsv) with an adjuvant and pharmaceutically acceptable carrier
US5885823A (en) 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
WO1998006835A2 (en) 1996-08-16 1998-02-19 The Texas A & M University System Modifying insect cell gylcosylation pathways with baculovirus expression vectors
EP0835930B1 (en) 1996-10-09 2001-01-31 Akzo Nobel N.V. European vaccine strains of the porcine reproductive and respiratory syndrome virus (PRRSV)
US20060029617A1 (en) 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US7211379B2 (en) 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US7192594B2 (en) 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
US20040062775A1 (en) 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
KR100879650B1 (ko) 1997-12-11 2009-01-20 유니버시티 오브 사스카췌완 돼지로부터의 이유후 다기관계작용성 소모 증후군 바이러스
AU770002B2 (en) 1998-03-13 2004-02-12 University Of Georgia Research Foundation, Inc., The Vaccines against circovirus infections
EP0953574A1 (en) 1998-04-30 1999-11-03 Innogenetics N.V. Immunodiagnostic reagent for the detection of Maedi-Visna virus and CAEV infection
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
DE69933647T2 (de) 1998-11-19 2007-08-23 Azwell Inc. Rekombinante lysophosphatidsäure - phosphatase.
FR2789695B1 (fr) 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
WO2001017556A1 (fr) 1999-09-07 2001-03-15 Shionogi & Co., Ltd. Préparations vaccinales administrables par les muqueuses
US6656478B1 (en) 1999-11-12 2003-12-02 Samuel D. Charles Cross-protective salmonella vaccines
DE60038048T2 (de) 1999-12-21 2009-07-09 Merial Mindestens ein cryptosporidium parvum-antigen und mindestens ein antigen eines anderen darmkrankheitserregers enthaltende zusammensetzungen und impfstoffe
US6808900B2 (en) 2000-06-15 2004-10-26 Manitoba, University Of Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
AU2001266940A1 (en) 2000-06-15 2001-12-24 Purdue Research Foundation Vaccine for congenital tremors in pigs
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
JP2002247979A (ja) 2001-02-23 2002-09-03 Nippon Biologicals Inc マレック病ワクチンおよびその製造方法
JP4038127B2 (ja) 2001-03-27 2008-01-23 ユニバーシティ オブ サスカチュワン サーコウイルスの培養方法
US20030096377A1 (en) 2001-06-28 2003-05-22 Virginia Tech Intellectual Properties, Inc. Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2
DK2027873T3 (en) 2001-07-02 2015-11-09 Zoetis Services Llc Single Dose Vaccination with Mycoplasma hyopneumoniae
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US6841364B2 (en) 2002-01-22 2005-01-11 Protatek International, Inc. Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
WO2003068163A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
US20030199581A1 (en) 2002-03-13 2003-10-23 Seligson Allen L. Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid ("AKBA") industrial manufacture and uses
US20030215455A1 (en) 2002-05-14 2003-11-20 Bailey Reynolds Vaccine stabilizer and method of use
AU2002951692A0 (en) 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
DK1599164T3 (en) 2003-02-03 2015-04-27 Cerebus Biolog Inc METHODS OF TREATMENT, PREVENTION AND DETECTION OF HELICOBACTER INFECTION
US7563449B2 (en) 2003-04-21 2009-07-21 Pfizer Inc, Methods for reducing cattle reproductive diseases
CN1458167A (zh) 2003-06-02 2003-11-26 中国农业科学院哈尔滨兽医研究所 截短表达的猪圆环病毒ⅱ型衣壳蛋白抗原及其应用
US7335361B2 (en) 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
CN1852735B (zh) 2003-07-24 2011-05-11 梅瑞尔有限公司 包含水包油乳液的疫苗制剂
US7312065B2 (en) 2003-07-25 2007-12-25 Boehringer Ingelheim Vetmedica, Inc. Lawsonia intracellularis of European origin and vaccines, diagnostic agents and methods of use thereof
FR2861731B1 (fr) 2003-10-30 2006-02-24 Centre Nat Rech Scient Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
WO2005112995A1 (en) 2004-04-26 2005-12-01 Choongang Vaccine Laboratory Co., Ltd. Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof
CN1579553A (zh) 2004-05-18 2005-02-16 浙江大学 Ii型猪圆环病毒核酸疫苗的制备方法及其应用
AU2005319716A1 (en) 2004-06-30 2006-06-29 Id Biomedical Corporation Of Quebec Vaccine compositions for treating coronavirus infection
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
ES2343201T3 (es) 2005-01-13 2010-07-26 Boehringer Ingelheim Vetmedica Gmbh Vacunas contra el srrp.
US7300785B2 (en) 2005-02-03 2007-11-27 Universiteit Ghent Culturing circular ssDNA viruses for the production of vaccines
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
CA2604691C (en) 2005-04-13 2013-12-31 Merial Limited Method for porcine circovirus production and assays for monitoring production
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
UA95458C2 (ru) 2005-09-09 2011-08-10 Интервет Интернешонал Б.В. Вакцина против pcv-2 у mda-положительных поросят
PT3127551T (pt) 2005-12-29 2020-10-09 Boehringer Ingelheim Animal Health Usa Inc Composição imunogénica de pcv2 para atenuar os sintomas clínicos em porcos
PL1968630T3 (pl) 2005-12-29 2018-08-31 Boehringer Ingelheim Vetmedica, Inc. Multiwalentne immunogenne kompozycje PCV2
US20100136060A1 (en) 2006-11-22 2010-06-03 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
EP2859900A1 (en) 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
CN101558169B (zh) 2006-12-15 2017-08-04 贝林格尔.英格海姆维特梅迪卡有限公司 以pcv2抗原治疗猪
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
GB0712160D0 (en) * 2007-06-22 2007-08-01 Univ Ghent Methods and compositions in the treatment of procine circoviral infection
US20090017064A1 (en) 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
EP2225367A1 (en) 2007-12-21 2010-09-08 Wyeth LLC Methods and compositions for immunizing pigs against porcine circovirus
EP2242511A4 (en) 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
US20110033495A1 (en) 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
EP2547770B1 (en) 2010-03-16 2019-11-27 Virginia Tech Intellectual Properties, Inc. Live attenuated chimeric porcine circovirus vaccine
JP5719016B2 (ja) 2010-04-22 2015-05-13 コーニンクレッカ フィリップス エヌ ヴェ 皮膚接触ディテクタ
AU2010357208A1 (en) 2010-07-08 2013-02-21 United Biomedical, Inc. Designer peptide-based PCV2 vaccine
WO2012033911A2 (en) 2010-09-08 2012-03-15 The Johns Hopkins University Polyionic papilloma virus-like particle (vlp) vaccines
EP2564869A1 (en) 2011-09-02 2013-03-06 Ceva Sante Animale Synthetic capsid proteins and uses thereof
CN103122352B (zh) 2012-09-27 2015-02-11 华中农业大学 一种猪圆环病毒2型重组杆状病毒及制备方法和应用
EP3587439A3 (en) * 2013-03-01 2020-03-11 Boehringer Ingelheim Animal Health USA Inc. Improved quantification of vaccine compositions
EP2991676A1 (en) 2013-04-30 2016-03-09 Boehringer Ingelheim Vetmedica, Inc. Orf2 protein of pcv2 subtype a (pcv2a) for use in cross-protection
KR102409183B1 (ko) * 2013-10-02 2022-06-15 베링거 인겔하임 애니멀 헬스 유에스에이 인크. Ｐｃｖ2 ｏｒｆ2 단백질 변이체 및 이로 이루어진 바이러스 유사 입자
BR112016023983B1 (pt) 2014-05-07 2022-10-18 Boehringer Ingelheim International Gmbh Contentor para um nebulizador, nebulizador para um fluido e método para conectar um contentor a um dispositivo indicador
US10555994B2 (en) * 2015-03-30 2020-02-11 Boehringer Ingelheim Animal Health USA Inc. PCV2 ORF2 carrier platform

Also Published As

Publication number Publication date
KR20220083861A (ko) 2022-06-20
EA201600305A1 (ru) 2016-09-30
MX373884B (es) 2020-03-26
AU2014329524A1 (en) 2016-03-17
EP3052516B1 (en) 2020-01-01
US20190023747A1 (en) 2019-01-24
CA2924228C (en) 2024-01-16
US9505808B2 (en) 2016-11-29
US10131696B2 (en) 2018-11-20
AU2014329524B2 (en) 2019-01-17
KR102409183B1 (ko) 2022-06-15
US10961281B2 (en) 2021-03-30
KR20160058958A (ko) 2016-05-25
US20150093404A1 (en) 2015-04-02
US12247051B2 (en) 2025-03-11
CN105658660A (zh) 2016-06-08
US20170029471A1 (en) 2017-02-02
US20210221852A1 (en) 2021-07-22
DK3052516T3 (da) 2020-03-23
EP3052516A1 (en) 2016-08-10
JP6778104B2 (ja) 2020-10-28
JP2016534034A (ja) 2016-11-04
US20250243246A1 (en) 2025-07-31
ES2778425T3 (es) 2020-08-10
US11858963B2 (en) 2024-01-02
EA035265B1 (ru) 2020-05-21
WO2015051099A1 (en) 2015-04-09
US20240076321A1 (en) 2024-03-07
CA2924228A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
MX2016004063A (es) Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.
MX386403B (es) Anticuerpos humanos para hemaglutinina de influenza.
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
UA124347C2 (uk) Циклічна динуклеотидна сполука
WO2017191258A8 (en) INFLUENZA MRNA VACCINES
MX2018009917A (es) Vacuna contra el virus del zika.
EA201790630A1 (ru) Способы получения рибозидов
EA201690556A1 (ru) Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций
EP2985288A4 (en) PIGS PSEUDORABIESVIRUS, VACCINE COMPOSITION, AND METHOD OF PREPARATION AND USE THEREOF
MX2016016533A (es) Combinaciones inmunogenas.
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
MX2015014751A (es) Composiciones y metodos para el tratamiento de la inmunodeficiencia.
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
MX2017003117A (es) Particula tipo virus de flavivirus.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
CU20180035A7 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
CL2016000300A1 (es) Métodos terapéuticos
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
CL2011003002A1 (es) Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.

FG Grant or registration